Favipiravir induced nephrotoxicity in two patients of COVID-19
Journal of the Association of Physicians of India
; 69(June):85-85, 2021.
Article
in English
| GIM | ID: covidwho-1755998
ABSTRACT
This paper reports two cases of AKI with favipiravir induced nephrotoxicity. Patient 1 38-year male, confirmed reverse transcriptase polymerase chain reaction positive (RT-PCR) positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) and moderate pneumonia was given hydroxy-chloroquinine (HCQ) 400 mg BID followed by 200 mg BID for 10 days and favipiravir at 1600 mg BID followed by 600 mg BID for 5 days. Patient 2 51-year male RT-PCR positive, severe COVID-19 was started on HCQ and favipiravir at same dose as in patient one along with methylprednisolone 40 mg BID for days and enoxaparin 40 mg subcutaneous once daily. In conclusion, the authors believe as many repurposed drugs are being used for COVID-19 on experimental and compassionate basis without well conducted research, the clinicians need to be very careful of any new adverse event. The AKI like in any other patient needs comprehensive review for all possible etiology before linking it to COVID-19.
259793-96-9; 83-43-2; adverse effects; antiviral agents; case reports; clinical aspects; coronavirus disease 2019; drug therapy; drug toxicity; favipiravir; human diseases; kidneys; methylprednisolone; nephrotoxicity; viral diseases; man; Severe acute respiratory syndrome coronavirus 2; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; drug repositioning; adverse reactions; antivirals; clinical picture; chemotherapy; SARS-CoV-2; viral infections
Search on Google
Collection:
Databases of international organizations
Database:
GIM
Language:
English
Journal:
Journal of the Association of Physicians of India
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS